SCHEMBL4789524

SCHEMBL4789524

COC(=O)CC1CCN(C(=O)Nc2ccc([N+](=O)[O-])cc2)Cc2ccccc21

nearest known ligand 0.59

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 5/20 0.59
MEN1 O00255 4/20 0.59
KMT2A Q03164 4/20 0.59
GAA P10253 1/20 0.47
NPC1 O15118 4/20 0.46
ALDH1A1 P00352 2/20 0.45
LMNA P02545 2/20 0.45
MAPT P10636 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
HTT P42858 2/20 0.45
NAMPT P43490 6/20 0.43
TAS1R3 Q7RTX0 2/20 0.43
TAS1R1 Q7RTX1 2/20 0.43
TAS1R2 Q8TE23 2/20 0.43
EPHX2 P34913 1/20 0.43
THRB P10828 1/20 0.43
ATM Q13315 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4790682 0.86 NPC1 (0.47) RAB9AKMT2ANPC1ALDH1A1MAPT
SCHEMBL4718481 0.75 PTGDR2 (0.38) RAB9ANPC1ALDH1A1MAPTNAMPT
SCHEMBL3710550 0.75 MEN1 (0.82) RAB9AMEN1KMT2AGAANPC1
SCHEMBL3706890 0.75 RAB9A (1.00) RAB9AMEN1KMT2AGAANPC1
SCHEMBL4790954 0.74 NAMPT (0.47) NAMPT
SCHEMBL31455212 0.72 ALDH1A1 (0.68) RAB9AMEN1KMT2AGAAALDH1A1
SCHEMBL4791291 0.72 NAMPT (0.36) NAMPT
SCHEMBL14221973 0.71 NAMPT (0.46) RAB9AMEN1KMT2ANPC1SMN1; SMN2
SCHEMBL31455191 0.70 GAA (0.61) RAB9AMEN1KMT2AGAAALDH1A1
SCHEMBL28363737 0.69 GAA (0.64) RAB9AMEN1KMT2AGAANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1216230-B1 FUSED CYCLOHEPTANE AND FUSED AZACYCLOHEPTANE COMPOUNDS AND THEIR USE AS INTEGRIN RECEPTOR ANTAGONISTS AMGEN INC (US) 2008-04-23 EP disclosed
US-6514964-B1 Treating diseases, conditions or disorders mediated by integrin receptors, such as vitronectin and fibronectin receptors AMGEN INC. 2003-02-04 US disclosed